News Related to Targeted Lipid Nanoparticles

Related coverage linked through entity extraction aliases.

Lonza Advances ADC Capabilities with Engitix Licensing Deal and Advanced Synthesis Expansion

Jul 24, 2026

Lonza announced a licensing agreement with Engitix to develop ADCs using its technology platform, alongside an expansion of its Advanced Synthesis offering that integrates GlycoConnect, HydraSpace, and toxSYN technologies. The Oss site has been upgraded to support bioconjugate R&D and pilot toxicology supply.

LigaChem Accelerates ADC Pipeline Amid Losses, Lonza Expands Bioconjugate Capabilities

Apr 08, 2026

LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.